Medication Side-Effects for Capaxive

← Back to Index

General Information

Manufacturer:Merck

Medical Name: Pneumococcal 21-valent Conjugate Vaccine

Purpose:Capaxive is a vaccine for individuals 18 years of age and older to help protect against invasive pneumococcal disease and pneumonia caused by certain types of bacteria called pneumococcus.

Side Effects

The likelihood of side effects can vary slightly by age group. The percentages below represent the rate of "solicited" (specifically looked for) adverse reactions reported within 5 days post-vaccination across clinical studies.
Side-Effect Adults 18–49 years Adults 50+ years
Injection site pain 73.1% 41.2%
Fatigue (tiredness) 36.0% 19.7%
Headache 27.5% 11.0%
Myalgia (muscle pain) 16.4% <10% (e.g., 8.7% in one study)
Injection site redness 13.8% <10%
Injection site swelling 13.3% <10%
Fever (≥100.4°F/38.0°C) ~3% (incidence of any fever, not all >10%) ~3% (incidence of any fever, not all >10%)

Serious but Less Common Side Effects

Serious adverse events (SAEs) are rare. In clinical trials, the proportion of individuals reporting one or more SAEs within one month of vaccination was low and comparable between the Capvaxive and comparator groups, at 0.3%.

One individual experienced a severe allergic reaction (bronchospasm) shortly after vaccination, and another had injection-site cellulitis (a serious skin infection).

Contraindications

You should not receive Capvaxive if you have a history of a severe allergic reaction (anaphylaxis) to any component of the vaccine or to diphtheria toxoid.

Precautions and Conditions Requiring Consultation

Seek immediate medical attention if you experience symptoms of a severe allergic reaction after vaccination, such as:

References